Kancera reports that the company has registered a patent application (EP14167988.6) for new compounds against cancer that selectively inhibit the enzyme HDAC6. The new patent application is based on the ability of HDAC6 inhibitors to influence mechanisms both inside...
Read MoreIn 2013, a collaboration was initiated between Kancera and Professor Thomas Helleday at the Science for Life Laboratory, Karolinska Institutet , in order to advance unique research on metabolism of cancer and PFKFB3 as a target for drug development....
Read MoreAll figures from the first quarter 2013 relate only to Kancera AB as a consequence of the liquidation of the subsidiary iNovacia AB in the beginning of 2013. Therefore there are no consolidated accounts for the Kancera Group produced...
Read MoreKancera reports that the company is initiating the development of a vaccine directed against ROR. This initiative is motivated by the residual disease in the form of a small number of cancer cells that remain in some patients despite...
Read MoreKancera announces the discovery of a new class of compounds that inhibits the epigenetic enzyme histone deacetylase 6 (HDAC6) and thereby controls the activity of the cancer cell genes. Severe side effects, due to poor selectivity, have limited the...
Read MoreAll figures from the first quarter 2013 relate only to Kancera AB as a consequence of the liquidation of the subsidiary iNovacia AB in the beginning of 2013. Therefore there are no consolidated accounts for the Kancera Group produced...
Read MoreAll figures from the first quarter 2013 relate only to Kancera AB as a consequence of the liquidation of the subsidiary iNovacia AB in the beginning of 2013. Therefore there are no consolidated accounts for the Kancera Group produced...
Read MoreKancera together with international research groups in the project A-PARADDISE has been awarded a grant from the European Union Seventh Framework Programme to develop drugs to combat severe parasitic diseases including malaria, schistosomiasis, leishmaniasis and Chagas disease. The total...
Read MoreKancera reports progress in the development of a ROR-inhibiting cancer drug. The compound KAN0439365 is effective against cancer cells from patients and show good metabolic stability in human liver cells and blood. KAN0439365 is the first in a new...
Read MoreJanuary 1 - March 31, 2013 All figures from the first quarter 2013 relate only to Kancera AB as a consequence of the liquidation of the subsidiary iNovacia AB. Therefore there are no consolidated accounts for the Kancera Group...
Read More